In clinical trials of BTK monotherapy, the ORR of GCB-type DLBCL has been consistently lower (approximately 5–20%) than that of ABC type DLBCL8,18, and this tendency seems consistent in the R2A regimen. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.